Bavencio as first-line maintenance was associated with long-term efficacy in advanced urothelial carcinoma regardless of ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.

Approval was based on improved survival outcomes vs platinum-based chemotherapy as demonstrated in the phase 3 NIAGARA study.

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

Acrivon Therapeutics is halting work on developing its lead drug for ovarian and bladder cancers, instead focusing the Eli ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab) perioperative regimen has been approved by the US Food and Drug ...

Deaths among hospitalized patients with bladder cancer in the United States significantly increased from 4.5% in 2008 to 4.9% in 2021, driven by increased mortality among specific subgroups, ...

The promotional effort from Ferring features bladder cancer survivors sharing the news of a new treatment option.